148 related articles for article (PubMed ID: 8088021)
1. The use of activated clotting times to monitor heparin therapy during and after interventional procedures.
Bowers J; Ferguson JJ
Clin Cardiol; 1994 Jul; 17(7):357-61. PubMed ID: 8088021
[TBL] [Abstract][Full Text] [Related]
2. Use of the activated clotting time in anticoagulation monitoring of intravascular procedures.
Bowers J; Ferguson JJ
Tex Heart Inst J; 1993; 20(4):258-63. PubMed ID: 8298321
[TBL] [Abstract][Full Text] [Related]
3. Comparison of activated clotting times to heparin management test for adequacy of heparin anticoagulation in percutaneous transluminal coronary angioplasty.
Helft G; Choktron S; Beygui F; Le Feuvre C; Elalamy I; Metzger JP; Vacheron A; Samama MM
Cathet Cardiovasc Diagn; 1998 Nov; 45(3):329-31. PubMed ID: 9829899
[TBL] [Abstract][Full Text] [Related]
4. Activated clotting times and activated partial thromboplastin times in patients undergoing coronary angioplasty who receive bolus doses of heparin.
Dougherty KG; Gaos CM; Bush HS; Leachman DR; Ferguson JJ
Cathet Cardiovasc Diagn; 1992 Aug; 26(4):260-3. PubMed ID: 1394411
[TBL] [Abstract][Full Text] [Related]
5. Research review: use of activated clotting time to monitor heparin therapy in coronary patients.
Noureddine SN
Am J Crit Care; 1995 Jul; 4(4):272-7; quiz 278-9. PubMed ID: 7663590
[TBL] [Abstract][Full Text] [Related]
6. When we "act" on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures.
Klein LW; Agarwal JB
Cathet Cardiovasc Diagn; 1996 Feb; 37(2):154-7. PubMed ID: 8808071
[TBL] [Abstract][Full Text] [Related]
7. Bedside monitoring of heparin therapy: comparison of activated clotting time to activated partial thromboplastin time.
Reiner JS; Coyne KS; Lundergan CF; Ross AM
Cathet Cardiovasc Diagn; 1994 May; 32(1):49-52. PubMed ID: 8039220
[TBL] [Abstract][Full Text] [Related]
8. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
Ganter MT; Monn A; Tavakoli R; Genoni M; Klaghofer R; Furrer L; Honegger H; Hofer CK
Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
[TBL] [Abstract][Full Text] [Related]
9. Adequate heparinization during PTCA: assessment using activated clotting times.
Ogilby JD; Kopelman HA; Klein LW; Agarwal JB
Cathet Cardiovasc Diagn; 1989 Dec; 18(4):206-9. PubMed ID: 2605621
[TBL] [Abstract][Full Text] [Related]
10. Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.
Tsimikas S; Beyer R; Hassankhani A
J Thromb Thrombolysis; 2001 May; 11(3):217-21. PubMed ID: 11577260
[TBL] [Abstract][Full Text] [Related]
11. Correlations between activated clotting time values and heparin concentration measurements in young infants undergoing cardiopulmonary bypass.
Guzzetta NA; Monitz HG; Fernandez JD; Fazlollah TM; Knezevic A; Miller BE
Anesth Analg; 2010 Jul; 111(1):173-9. PubMed ID: 20519414
[TBL] [Abstract][Full Text] [Related]
12. Clinical safety and cost of heparin titration using bedside activated clotting time.
Thomason T; Riegel B; Jessen D; Smith SC; Gocka I; Rich M
Am J Crit Care; 1993 Jan; 2(1):81-7. PubMed ID: 8353584
[TBL] [Abstract][Full Text] [Related]
13. Activated clotting-time variability in patients undergoing coronary angioplasty.
Warner MF; Mian MS; Missri JC
Clin Cardiol; 1994 Jul; 17(7):372-4. PubMed ID: 8088023
[TBL] [Abstract][Full Text] [Related]
14. Preprocedural anticoagulation does not reduce angioplasty heparin requirements.
Blumenthal RS; Wolff MR; Resar JR; Coombs VJ; Brinker JA
Am Heart J; 1993 May; 125(5 Pt 1):1221-5. PubMed ID: 8480572
[TBL] [Abstract][Full Text] [Related]
15. Heparin monitoring during coronary intervention: activated clotting time versus activated partial thromboplastin time.
Nath FC; Muller DW; Rosenschein U; Ellis SG; Topol EJ
Can J Cardiol; 1993 Nov; 9(9):797-801. PubMed ID: 8281479
[TBL] [Abstract][Full Text] [Related]
16. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations.
Despotis GJ; Summerfield AL; Joist JH; Goodnough LT; Santoro SA; Spitznagel E; Cox JL; Lappas DG
J Thorac Cardiovasc Surg; 1994 Dec; 108(6):1076-82. PubMed ID: 7983877
[TBL] [Abstract][Full Text] [Related]
17. Heparin monitoring in the coronary care unit after percutaneous transluminal coronary angioplasty.
Varah N; Smith J; Baugh RF
Heart Lung; 1990 May; 19(3):265-70. PubMed ID: 2341265
[TBL] [Abstract][Full Text] [Related]
18. Laboratory monitoring of heparin and the combination of heparin and the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) in patients undergoing percutaneous transluminal coronary angioplasty (PTCA).
Zahn R; Haubelt H; Bechtloff S; Schneider S; Frilling B; Rustige J; Marsalek P; Seidl K; Senges J; Hellstern P
Herz; 2003 Aug; 28(5):445-52. PubMed ID: 12928744
[TBL] [Abstract][Full Text] [Related]
19. Activated clotting time monitoring of intraoperative heparinization: our experience and comparison of two techniques.
Mabry CD; Thompson BW; Read RC; Campbell GS
Surgery; 1981 Nov; 90(5):889-95. PubMed ID: 7302842
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of a new point of care heparin test for cardiopulmonary bypass: the TAS heparin management test.
Wallock M; Jeske WP; Bakhos M; Walenga JM
Perfusion; 2001 Mar; 16(2):147-53. PubMed ID: 11334198
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
